Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KJ Pyr 9 是一种 MYC 的抑制剂,在体外实验中的 Kd 值为 6.5 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 259 | 现货 | ||
5 mg | ¥ 448 | 现货 | ||
10 mg | ¥ 728 | 现货 | ||
25 mg | ¥ 1,290 | 现货 | ||
50 mg | ¥ 2,190 | 现货 | ||
100 mg | ¥ 3,490 | 现货 | ||
200 mg | ¥ 4,670 | 现货 | ||
500 mg | ¥ 7,380 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 490 | 现货 |
产品描述 | KJ Pyr 9 is an MYC inhibitor (Kd: 6.5 nM in vitro assay). |
靶点活性 | MYC:(kd)6.5±1.0 nM |
体外活性 | KJ Pyr 9 specifically inhibits MYC-induced oncogenic transformation in cell culture; it has no or only weak effects on the oncogenic activity of several unrelated oncoproteins. KJ Pyr 9 interferes with MYC-MAX complex formation in the cell, as shown in a protein fragment complementation assay. KJ Pyr 9 against three cell lines is tested known to be dependent on increased MYC activity: NCI-H460, MDA-MB-231, and SUM-159PT. KJ Pyr 9 preferentially interferes with the proliferation of MYC-overexpressing human and avian cells and specifically reduces the MYC-driven transcriptional signature. The proliferation of all cell lines tested is inhibited (IC50s: between 5 and 10 μM). The proliferation of Burkitt lymphoma cell lines, which show constitutively high expression of c-MYC, is more sensitive to KJ Pyr 9 (IC50s: between 1 and 2.5 μM). |
体内活性 | Nude mice receive a xenograft of MDA-MB-231 cells suspended in Matrigel and injected s.c. into the left and right flanks to test the in vivo effectiveness of KJ Pyr 9 (KJ-Pyr-9). The tumor volume in the KJ Pyr 9-treated animals has not increased significantly, by day 31. The tumors are extracted and weighed, at the conclusion of the experiment. When the tumors have reached an average volume of 100 mm3, mice are treated daily with 10 mg/kg KJ Pyr 9 or vehicle control by i.p. injection for 31 d. Inhibition of tumor growth by KJ Pyr 9 is noted after 8 d of treatment. The weight measurements are in agreement with the volume determinations and confirmed the ability of KJ Pyr 9 to halt tumor growth. |
分子量 | 385.37 |
分子式 | C22H15N3O4 |
CAS No. | 581073-80-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (259.49 mM), Sonification is recommended.
H2O: < 0.1 mg/mL (insoluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5949 mL | 12.9745 mL | 25.9491 mL | 64.8727 mL |
5 mM | 0.519 mL | 2.5949 mL | 5.1898 mL | 12.9745 mL | |
10 mM | 0.2595 mL | 1.2975 mL | 2.5949 mL | 6.4873 mL | |
20 mM | 0.1297 mL | 0.6487 mL | 1.2975 mL | 3.2436 mL | |
50 mM | 0.0519 mL | 0.2595 mL | 0.519 mL | 1.2975 mL | |
100 mM | 0.0259 mL | 0.1297 mL | 0.2595 mL | 0.6487 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
KJ Pyr 9 581073-80-5 Autophagy Cell Cycle/Checkpoint c-Myc KJ Pyr9 inhibit Inhibitor Myc KJ Pyr-9 inhibitor